(Q38730623)

5 September 2017

title

PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs (English)

1 reference

5 September 2017

1

Peter L Turecek

1 reference

5 September 2017

Mary J Bossard

2

1 reference

5 September 2017

Freddy Schoetens

series ordinal

3

1 reference

5 September 2017

Inge A Ivens

series ordinal

4

1 reference

5 September 2017

language of work or name

English

0 references

publication date

1 February 2016

1 reference

Journal of Pharmaceutical Sciences

5 September 2017

published in

1 reference

5 September 2017

volume

105

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

460-475

1 reference

Protein, peptide and non-peptide drug PEGylation for therapeutic application

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Chemistry for peptide and protein PEGylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Functionalized Poly(ethylene glycols) for Preparation of Biologically Relevant Conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Anti-inflammatory and pharmacokinetic properties of superoxide dismutase derivatized with polyethylene glycol via active esters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Effective drug delivery by PEGylated drug conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Polyethylene glycol modification: relevance of improved methodology to tumour targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEGylation, successful approach to drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEGylation of therapeutic proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

State of the art in PEGylation: the great versatility achieved after forty years of research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Releasable PEGylation of proteins with customized linkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

7 January 2021

Emerging PEGylated drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Effect of PEGylation on protein hydrodynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Probing protein structure by amino acid-specific covalent labeling and mass spectrometry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Spectroscopic characterization of polyethyleneglycol modified superoxide dismutase: 1H NMR studies on its Cu2Co2 derivative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

A comparative study of enzymatic, structural, and pharmacokinetic properties of superoxide dismutase isolated from two sources and modified by monomethoxypolyethylene glycol using different methods of coupling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Effects of PEG conjugation on insulin properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEGylation of human serum albumin: reaction of PEG-phenyl-isothiocyanate with protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Site-specific pegylation of G-CSF by reversible denaturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Increased activity and stability of poly(ethylene glycol)-modified trypsin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Effects of monomethoxypoly(ethylene glycol) modification of ribonuclease on antibody recognition, substrate accessibility and conformational stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Preferential Interactions and the Effect of Protein PEGylation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Effects of PEG size on structure, function and stability of PEGylated BSA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Characterisation and physical stability of PEGylated glucagon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Stabilization of alpha-chymotrypsin upon PEGylation correlates with reduced structural dynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Structure-Function Perturbation and Dissociation of Tetrameric Urate Oxidase by High Hydrostatic Pressure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Biochemical and biopharmaceutical properties of PEGylated uricase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Biophysical characterisation of GlycoPEGylated recombinant human factor VIIa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Characterization and stability of N-terminally PEGylated rhG-CSF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

The effect of protein PEGylation on physical stability in liquid formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

A simple modified carbodiimide method for conjugation of small-molecular-weight compounds to immunoglobulin G with minimal protein crosslinking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Labeling glycoconjugates with hydrazide reagents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Aminooxy-, Hydrazide-, and Thiosemicarbazide-Functionalized Saccharides: Versatile Reagents for Glycoconjugate Synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Anti-cancer PEG-enzymes: 30 years old, but still a current approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEG conjugates in clinical development or use as anticancer agents: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Amino acid sequence of L-asparaginase from Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Instability of succinyl ester linkages in O2'-monosuccinyl cyclic AMP-protein conjugates at neutral pH.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

L-asparaginase and PEG asparaginase--past, present, and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Pegaspargase: a review of clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEG-uricase in the management of treatment-resistant gout and hyperuricemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Identification of the major positional isomer of pegylated interferon alpha-2b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

A branched monomethoxypoly(ethylene glycol) for protein modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Pegvisomant in the treatment of acromegaly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Long-acting growth hormones produced by conjugation with polyethylene glycol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Management of viral hepatitis: clinical and public health perspectives--a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Mono-N-terminal poly(ethylene glycol)-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Formulation of Neulasta (pegfilgrastim).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

PEGylated antibodies and antibody fragments for improved therapy: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Therapeutic antibody fragments with prolonged in vivo half-lives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Certolizumab pegol for the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

The structure of 2Zn pig insulin crystals at 1.5 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.XPHS.2015.11.015

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.XPHS.2015.11.015

1 reference

5 September 2017

1 reference